Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC
Shun Lu(Shanghai Chest Hospital), Suresh S. Ramalingam(Roche (Switzerland)), Ignacio Casarini(Cancer Hospital of Chinese Academy of Medical Sciences), Takako Inoue(Osaka International Cancer Institute), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Toon van der Gronde(Cancer Hospital of Chinese Academy of Medical Sciences), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Myung‐Ju Ahn(Samsung Medical Center), Nopadol Soparattanapaisarn(Cancer Hospital of Chinese Academy of Medical Sciences), Meijuan Huang(Cancer Hospital of Chinese Academy of Medical Sciences), Eduardo Cronemberger(Cancer Hospital of Chinese Academy of Medical Sciences), James Chih‐Hsin Yang(National Taiwan University), Dana Ghiorghiu(AstraZeneca (United Kingdom)), Xiaorong Dong(Huazhong University of Science and Technology), Terufumi Kato(Taipei Veterans General Hospital), Dang-Van Khiem(Cancer Hospital of Chinese Academy of Medical Sciences), Ming Chen(Sun Yat-sen University), Virote Sriuranpong(Chinese University of Hong Kong), Xiangning Huang(AstraZeneca (United Kingdom)), Y. Runglodvatana(Cancer Hospital of Chinese Academy of Medical Sciences), Le-Van Quang(Cancer Hospital of Chinese Academy of Medical Sciences), Chih-Liang Wang(Cancer Hospital of Chinese Academy of Medical Sciences), Ellie Grainger(Cancer Hospital of Chinese Academy of Medical Sciences), Toshiaki Takahashi(Shizuoka Cancer Center)
Cited by 291
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k